Locally Advanced or Metastatic Urothelial Carcinoma (UC) Clinical Trial
Official title:
A Multicenter, Open-label, Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma (EV-901)
| NCT number | NCT04136808 |
| Other study ID # | 7465-CL-0108 |
| Secondary ID | |
| Status | Approved for marketing |
| Phase | |
| First received | |
| Last updated |
| Verified date | January 2020 |
| Source | Astellas Pharma Inc |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Expanded Access |
The primary purpose of this expanded access program is to evaluate safety and tolerability of enfortumab vedotin (EV) in participants in the United States with locally advanced or metastatic urothelial carcinoma (UC) who have exhausted standard of care therapies and are not eligible to participate in an ongoing EV clinical study. This program will also evaluate the efficacy of EV.
| Status | Approved for marketing |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Subject has locally advanced or metastatic urothelial carcinoma (UC) and has progressed during or after the most recent therapy. - Subject has previously received a platinum containing regimen (i.e., cisplatin or carboplatin) in the metastatic/locally advanced or neoadjuvant/adjuvant setting. - If the platinum containing regimen was administered in the adjuvant/neoadjuvant setting, progression on or after this treatment must be = 12 months after treatment completion. - Subject has previously received treatment with a programmed cell death protein 1 (PD-1) inhibitor or programmed death-ligand 1 (PD-L1) inhibitor (including, but not limited to, atezolizumab, pembrolizumab, durvalumab, avelumab and nivolumab) in the metastatic/locally advanced setting. - Subject treated with a PD-1 or PD-L1 inhibitor in the neoadjuvant/adjuvant setting and had recurrent or progressive disease either during therapy or = 3 months of therapy completion may be enrolled. - Subject has exhausted available standard of care therapies for locally advanced or metastatic UC. - Subject may have had any number of prior lines of therapy for locally advanced or metastatic UC. - Subject has the following baseline laboratory data: - absolute neutrophil count = 1500/mm3 - platelet count = 75 x 109/L - hemoglobin = 8 g/dL - serum bilirubin = 1.5 x upper limit of normal (ULN) or = 3 x ULN for subjects with Gilbert's disease - creatinine clearance (CrCl) = 15 mL/min or = 30 mL/min for subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 2 as estimated per institutional standards or as measured by 24 hour urine collection (glomerular filtration rate can also be used instead of CrCl) - alanine aminotransferase and aspartate aminotransferase = 2.5 x ULN or = 3 x ULN for subjects with liver metastases - Subject has ECOG performance status of 0, 1 or 2. - Female subject is not pregnant and at least 1of the following conditions apply: - not a woman of childbearing potential (WOCBP), or - a WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after final protocol treatment administration. - Female subject must agree not to breastfeed starting at screening and throughout the treatment protocol period and for 6 months after final protocol treatment administration. - Female subject must not donate ova starting at first dose of investigational product (IP) and throughout the treatment protocol period and for 6 months after final protocol treatment administration. - Male subject with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 6 months after final protocol treatment administration. - Male subject must not donate sperm during the treatment period and for 6 months after final protocol treatment administration. - Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the treatment protocol period and for 6 months after final protocol treatment administration. - Subject agrees not to participate in another interventional study while receiving treatment in the present treatment protocol. Exclusion Criteria: - Subject has ongoing sensory or motor neuropathy grade = 2. - Subject has ongoing clinically significant toxicity (grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery). Subject with hypothyroidism or panhypopituitarism related to treatment with PD-1 and PD-L1 inhibitors may be enrolled. Subject on hormone replacement therapy may be enrolled if on a stable dose. - Subject has ongoing immunotherapy related myocarditis, colitis, uveitis or pneumonitis or other immunotherapy related toxicities requiring high doses of steroids (> 20 mg/day of prednisone or equivalent). - Subject has previously received EV or enrolled in an EV study or a study that included EV as one of the treatment options (even if the subject was not given EV). - Subject is a candidate for any ongoing EV clinical studies. - Subject has known hypersensitivity to EV or to any excipient contained in the drug formulation of EV. - Subject completed radiotherapy, major surgery or prior anticancer therapy = 2 weeks before first EV dose. - Subject has history of uncontrolled diabetes mellitus = 3 months of the first EV dose. Uncontrolled diabetes is defined as hemoglobin A1C (HbA1c) = 8% or HbA1c between 7 and < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. - Subject is currently receiving systemic antimicrobial treatment for viral, bacterial or fungal infection at the time of first dose of EV. Routine antimicrobial prophylaxis is permitted. - Subject has recent history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Classes III to IV that is not adequately treated and/or controlled at the time of first EV dose. - Subject has other underlying medical condition that would impair the ability of the subject to receive or tolerate EV. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Community Hospital Anderson | Anderson | Indiana |
| United States | Johns Hopkins University | Baltimore | Maryland |
| United States | Levine Cancer Institute | Charlotte | North Carolina |
| United States | Northwestern University Medical Center | Chicago | Illinois |
| United States | University of Chicago | Chicago | Illinois |
| United States | Geisinger Medical Center | Danville | Pennsylvania |
| United States | Duke University Medical Center | Durham | North Carolina |
| United States | Inova Schar Cancer Institute | Fairfax | Virginia |
| United States | Holy Cross Hospital | Fort Lauderdale | Florida |
| United States | Cancer Specialists of North Florida | Jacksonville | Florida |
| United States | UCLA Hematology Oncology | Los Angeles | California |
| United States | NYU Langone Health | New York | New York |
| United States | John Wayne Cancer Institute | Santa Monica | California |
| United States | St. Joseph Heritage Medical Group | Santa Rosa | California |
| United States | New England Cancer Specialists | Topsham | Maine |
| Lead Sponsor | Collaborator |
|---|---|
| Astellas Pharma Global Development, Inc. | Seattle Genetics, Inc. |
United States,